Insider · CIK 0001238401
Louis G Lange
director
Files at NAMS (NewAmsterdam Pharma Co N.V.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares | +3,102 | $0.00 | $0 | 10,062 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Restricted Stock Unitderivative | +3,308 | - | - | 3,308 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Restricted Stock Unitderivative | -3,102 | - | - | 206 | Mar 28, 2025 |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Ordinary Shares | +6,960 | - | - | 6,960 | Jan 8, 2025 |
| Jan 6, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Option (right to buy)derivative | +32,500 | $0.00 | $0 | 32,500 | Jan 8, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.